SymBio Pharmaceuticals Limited
SYMQY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $383 | $264 | $554 |
| % Growth | -99.4% | 44.9% | -52.3% | – |
| Cost of Goods Sold | $1 | $91 | $62 | $125 |
| Gross Profit | $1 | $291 | $202 | $429 |
| % Margin | 62.3% | 76.1% | 76.7% | 77.4% |
| R&D Expenses | $6 | $819 | $819 | $886 |
| G&A Expenses | $0 | $0 | $0 | $151 |
| SG&A Expenses | $4 | $4 | $552 | $628 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $692 |
| Other Operating Expenses | $0 | $453 | $0 | -$1 |
| Operating Expenses | $9 | $1,276 | $1,372 | $1,514 |
| Operating Income | -$8 | -$985 | -$1,169 | -$1,085 |
| % Margin | -365.7% | -257.4% | -442.8% | -196% |
| Other Income/Exp. Net | -$0 | -$63 | -$141 | $103 |
| Pre-Tax Income | -$8 | -$1,048 | -$1,310 | -$982 |
| Tax Expense | -$0 | $0 | $12 | $6 |
| Net Income | -$8 | -$1,048 | -$1,321 | -$988 |
| % Margin | -369.1% | -273.8% | -500.5% | -178.5% |
| EPS | -0.16 | -22.16 | -27.95 | -21.55 |
| % Growth | 99.3% | 20.7% | -29.7% | – |
| EPS Diluted | -0.16 | -22.16 | -27.95 | -21.55 |
| Weighted Avg Shares Out | 50 | 47 | 47 | 46 |
| Weighted Avg Shares Out Dil | 50 | 47 | 47 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $9 |
| Interest Expense | $0 | $0 | $6 | $0 |
| Depreciation & Amortization | $0 | $985 | $1,169 | $25 |
| EBITDA | -$8 | -$7 | -$135 | -$1,061 |
| % Margin | -361.3% | -1.8% | -51.1% | -191.7% |